Home›Trial›NCT07161687
🔬NCT07161687ACTIVE NOT RECRUITING

A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

Study Summary

A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Conditions
Hemophilia A or B
Interventions / Drugs
Marstacimab
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F34/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.190437+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.